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Abstract
BACKGROUND—The Centers for Disease Control and Prevention initiated the Colorectal 
Cancer Screening Demonstration Program (CRCSDP) to explore the feasibility of establishing a 
large-scale colorectal cancer (CRC) screening program for underserved populations in the United 
States. The authors of this report assessed the clinical costs incurred at each of the 5 participating 
sites during the demonstration period.
METHODS—By using data on payments to providers by each of the 5 CRCSDP sites, the authors 
estimated costs for specific clinical services and overall clinical costs for each of the 2 CRC 
screening methods used by the sites: colonoscopy and fecal occult blood test (FOBT).
RESULTS—Among CRCSDP clients who were at average risk for CRC and for whom complete 
cost data were available, 2131 were screened by FOBT, and 1888 were screened by colonoscopy. 
The total average clinical cost per individual screened by FOBT (including costs for screening, 
diagnosis, initial surveillance, office visits, and associated clinical services averaged across all 
individuals who received screening FOBT) ranged from $48 in Nebraska to $149 in Greater 
Seattle. This compared with an average clinical cost per individual for all services related to the 
colonoscopy screening ranging from $654 in St. Louis to $1600 in Baltimore City.
CONCLUSIONS—Variations in how sites contracted with providers and in the services provided 
through CRCSDP affected the cost of clinical services and the complexity of collecting cost data. 
Health officials may find these data useful in program planning and budgeting.
Corresponding author: Florence K. L. Tangka, PhD, Division of Cancer Prevention and Control, Centers for Disease Control and 
Prevention, 4770 Buford Highway NE, Atlanta, GA 30341-3724; Fax: (770) 488-4639; ftangka@cdc.gov. 
The opinions or views expressed in this supplement are those of the authors and do not necessarily reflect the opinions or 
recommendations of the journal editors, the American Cancer Society, John Wiley & Sons, Inc., or the Centers for Disease Control 
and Prevention.
The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers 
for Disease Control and Prevention.
CONFLICT OF INTEREST DISCLOSURES
The authors made no disclosures.
The articles in this supplement were commissioned based on participation in evaluating the Centers for Disease Control and 
Prevention-funded Colorectal Cancer Screening Demonstration Program.
HHS Public Access
Author manuscript
Cancer. Author manuscript; available in PMC 2016 January 28.
Published in final edited form as:














clinical cost; cost assessment; colorectal cancer; cancer screening program; colorectal cancer
INTRODUCTION
Colorectal cancer (CRC) is the second leading cause of cancer-related deaths among adults 
in the United States, and CRC mortality and survival rates vary substantially by race.1,2 
Although there is strong scientific evidence that regular screening decreases CRC incidence 
and mortality rates, only about two-thirds of US residents for whom screening is 
recommended are screened at the intervals recommended by US Preventive Services Task 
Force guidelines.3 The rate of compliance with these screening guidelines is even lower 
(roughly 35%) among uninsured US residents.3 Screening programs that specifically target 
the uninsured were proposed to help reduce disparities along racial, ethnic, and 
socioeconomic lines in CRC screening, incidence, and mortality rates.4
In 2005, to explore the feasibility of establishing a national CRC screening program for 
underserved US populations, the Centers for Disease Control and Prevention (CDC) 
established the 4-year Colorectal Cancer Screening Demonstration Program (CRCSDP) at 5 
sites.5 CRCSDP funding was provided to the Maryland Department of Health and Mental 
Hygiene (for Baltimore City), the Missouri Department of Health and Senior Services (for 
St. Louis), the Nebraska Department of Health and Human Services (for a statewide 
program), the Stony Brook University Medical Center (for a university-based program in 
Suffolk County, NY), and Public Health-Seattle & King County (for a program in Greater 
Seattle). Funds were provided to support both clinical (screening, surveillance, and 
diagnostic services) and associated services (office visits and patient navigation) activities 
for patients aged ≥50 years. These activities are described elsewhere in this supplement to 
Cancer.6,7 The local programs contracted with a variety of providers and health care 
systems, including primary care providers (PCPs), gastroenterologists, surgeons, 
pathologists, gastroenterology centers, laboratories, hospitals, and community health clinics, 
to create provider networks required for CRC screening.5 The CDC created a policy manual 
to guide overall program implementation, and each site’s local program also created its own 
individual policy manual.5 The policy manuals described clinical services that were 
reimbursable by the CDC and specified reimbursement rates (generally the same as 
Medicare rates) for services that were identified by Current Procedure Terminology, 
HealthCare Common Procedure Coding System (HCPCS), or Ambulatory Payment 
Classification codes.8
The screening tests used by each site differed. Three sites selected a combination of guaiac-
based fecal occult blood test (FOBT) and colonoscopy. Nebraska selected FOBT as its 
primary screening test for individuals at average risk of developing CRC (for criteria, see 
below) and used colonoscopy for diagnosis and for screening those at above-average risk. 
Greater Seattle initially selected FOBT as its primary screening test for average-risk 
individuals but began to offer all individuals a choice of FOBT or colonoscopy for screening 
during the sixth month of screening. St. Louis initially used FOBT as its primary screening 
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test for individuals at average risk of developing CRC but changed to colonoscopy for all 
individuals 13 months after the start of screening because of a low response rate to FOBT 
screening. Because the resulting sample size was small, we do not report on FOBT 
screening in St. Louis. The sites in Baltimore City and Suffolk County, New York used 
colonoscopy as their primary screening test throughout the demonstration. Each site has 
been described in detail in previous articles,5,9 and each is also described elsewhere in this 
supplement to Cancer.6,7
We previously reported on the cost of program startup for the 5 screening programs.10 
Program costs for each site associated with operating the CRCSDP are presented elsewhere 
in this supplement to Cancer.11 Below, we provide a detailed description of the clinical 
costs of the CRCSDP from 2006 through 2009, including the cost of CRC screening by 
FOBT and by colonoscopy, the cost of diagnostic and surveillance colonoscopy, and the cost 
of CRC screening-associated office visits. For those programs that offered both FOBT and 
colonoscopy, we examine the costs of each method separately. Finally, we compare the 
average total clinical cost of FOBT screening with the average total cost of colonoscopy 
screening.
MATERIALS AND METHODS
The 5 sites extracted cost data for 2006 through 2009 from provider billing data and 
provided those data to the CDC in a standardized format using an instrument that was 
developed by RTI International and the CDC. These included HCPCS data on 
reimbursement for each category of service from the billing codes on bills that providers 
were required to submit for each service provided. Data included the amount charged and 
the amount paid for the service and the date the service was provided. When necessary, local 
programs also provided additional clinical cost data. For example, programs provided 
information on the costs of FOBT kits and laboratory services that were purchased in bulk 
and, thus, were not reported in the provider billing data.
Three data sets were created for the CRCSDP: clinical data, including patient characteristics 
and details on screening and diagnostic testing; program reimbursement data on the 
screening costs associated with the CRCSDP; and program-level cost data. The clinical data 
have been described in an earlier article, and the program-level cost data are described 
elsewhere in this supplement to Cancer.5,10,11 A unique identifier for each individual who 
was screened through the CRCSDP facilitated linkage between clinical and program 
reimbursement data sets and helped us 1) evaluate test indication, CRC risk status, and the 
diagnostic cascade for all billed procedures; 2) assess the completeness of screening cost 
data; and 3) identify procedures for which individual-level billing data were unavailable.
We used the linked data to identify the CRC risk status at the time of the procedure for each 
individual screened. To facilitate a cost comparison between FOBT screening and 
colonoscopy screening, we limited our analysis to those who were considered to be at 
“average risk” for CRC, as defined by the following criteria: 1) no personal or family history 
of CRC or adenomas, 2) no history of inflammatory bowel disease (ulcerative colitis or 
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Crohn disease), and 3) no history of genetic syndromes like familial adenomatous polyposis 
or Lynch syndrome (previously known as hereditary nonpolyposis colorectal cancer).
The linked data also helped to distinguish follow-up tests from repeat screening tests. We 
identified 3 types of follow-up tests: a clearance colonoscopy, which followed a complete 
screening colonoscopy and was required to investigate findings from the initial colonoscopy 
or to complete polyp removal; a diagnostic colonoscopy, which followed a positive FOBT 
screen; and a surveillance colonoscopy, which was recommended for patients who had an 
adenoma or CRC detected at their index colonoscopy. In addition to follow-up tests, we 
defined a repeat colonoscopy as a second colonoscopy required because the initial 
colonoscopy was either incomplete (the cecum was not reached) or inadequate.
We used the date of the procedure to determine whether a test was the initial screening test, 
a repeat test, or a follow-up test. For patients who had billing data for multiple tests, we 
assumed that the earliest test was a screening test and that any later tests were follow-up or 
repeat tests. We used the indicator for surveillance recommendation to identify patients who 
received a surveillance colonoscopy after an initial screening test and attributed any test fees 
incurred after the date of the first test to surveillance colonoscopy.
We excluded individuals who had missing or incomplete colonoscopy cost data (whether for 
screening or follow-up colonoscopy) and those for whom reported colonoscopy costs were 
less than $200, because these costs likely reflected only partial payments. We aggregated all 
colonoscopy costs (including costs for bowel preparation, anesthesia, pathology, and other 
clinical services for each colonoscopy) to the test level so that we could compare costs 
across sites.
We report the actual amounts reimbursed for clinical services incurred during the 
demonstration period. They do not reflect costs associated with follow-up procedures that 
were recommended but not performed under the CRCSDP or the full costs of surveillance 
(because many patients for whom surveillance colonoscopy was recommended did not 
receive it them until after the CRCSDP ended).
RESULTS
After we applied the exclusion criteria described above, our study sample consisted of 2131 
average-risk individuals who were screened with FOBT (1264 in Nebraska and 867 in 
Greater Seattle) and 1888 who were screened with colonoscopy (528 in Baltimore City, 227 
in St. Louis, 156 in Nebraska, 714 in Suffolk County, and 263 in Greater Seattle) (Table 1). 
The percentage of individuals who had office visits before being screened varied widely by 
site and by screening method. For example, whereas none of the individuals who were 
screened by FOBT in Nebraska had an associated office visit, 49% of those who were 
screened with FOBT in Greater Seattle did have an associated office visit. Among those who 
were screened with colonoscopy, the percentage with an associated office visit ranged from 
2% of those screened in Nebraska to 100% of those screened in Greater Seattle. No screened 
individuals in Suffolk County, New York, had a specific billable office visit, because 
providers there served patients who were referred by a PCP, and payment for the already 
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scheduled primary care visit was handled outside of the program.12 In addition, the 
precolonoscopy visit was handled over the telephone by the lead PCP in this program, who 
was in close contact with the participating program gastroenterologists. This process used by 
Suffolk County, as described elsewhere in this supplement to Cancer, ensured that screened 
individuals met criteria for both medical and financial eligibility for the CRCSDP.12,13
Diagnostic colonoscopies to follow-up on a positive FOBT were performed for 3% of 
patients screened in Nebraska and 8% of those screened in Greater Seattle. Repeat 
colonoscopy because of an incomplete screening colonoscopy was required by less than 5% 
of patients in each of the programs. Clearance colonoscopies to investigate initial findings or 
to complete polyp removal were performed on a small percentage of patients in Baltimore 
City and Suffolk County, New York.
Among individuals who were screened with FOBT, 5% or less had positive diagnostic 
colonoscopy results indicating a need for surveillance colonoscopy. At most 2% of those 
screened by colonoscopy required surveillance colonoscopies in Baltimore City, St. Louis, 
and Suffolk County, New York. None of those screened with colonoscopy in Nebraska or 
Greater Seattle required surveillance colonoscopy.
The unit cost of screening tests, follow-up tests, and office visits all varied substantially by 
site and by type of screening method, as indicated in Table 2. Although the cost per FOBT 
screening was approximately $15 for both programs, the component costs varied between 
Nebraska ($3 per kit and $12 for processing) and Greater Seattle ($7 per kit and $9 for 
patient coordination). The average cost of an office visit associated with FOBT screening 
was $58 in Greater Seattle.
The average cost of a screening colonoscopy ranged from $610 in St. Louis to $1477 in 
Baltimore City, and the average cost of an office visit associated with a screening 
colonoscopy ranged from $21 in St. Louis to $123 in Greater Seattle. Although the average 
cost of a diagnostic colonoscopy was similar in Greater Seattle and Nebraska, the average 
cost of a surveillance colonoscopy in Baltimore City was more than double the cost in St. 
Louis. The average cost of a clearance colonoscopy (approximately $1500) is likely higher 
than that of a diagnostic colonoscopy at the same facilities because of higher pathology costs 
associated with extensive polyp removal.
The distribution of total costs among screening, diagnosis, initial surveillance (the first 
surveillance colonoscopy), and office visits varied among the sites and by screening test. 
These variations reflect differences in how each program was organized, which services 
were provided, and how a program paid for clinical tests and services. Among the FOBT 
programs, the screening test represented a small share of the total clinical cost per screened 
individual; whereas, in colonoscopy programs, the screening test represented the majority of 
total clinical cost.
The total average clinical cost per individual screened by FOBT (including costs for 
screening, diagnosis, initial surveillance, office visits, and associated clinical services) was 
$49 in Nebraska and $148 in Greater Seattle. Although the cost of screening and diagnostic 
tests as a share of total clinical costs in an FOBT screening program were similar in 
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Nebraska and Greater Seattle, the distribution of other clinical costs varied. In Nebraska, 
laboratory costs for developing the FOBT accounted for 25% of the total per person clinical 
costs. Greater Seattle did not reimburse providers for developing the test but spent a similar 
share on patient coordination (6%) and office visits (19%). The cost of the first surveillance 
colonoscopy was 6% of total per person clinical costs in Nebraska and 3% in Greater 
Seattle.
The average per person clinical cost related to the screening procedure in a colonoscopy 
screening program ranged from $654 in St. Louis to $1600 in Baltimore City. The cost of 
screening tests as a share of total clinical costs in a colonoscopy screening program was 
greater than 80% for all programs. Repeat colonoscopy (after an incomplete screening 
colonoscopy) generally represented a very small share of total per person clinical costs. 
Clearance colonoscopies (to investigate previous findings or to complete polyp removal 
after a completed screening colonoscopy) were performed in Baltimore City and Suffolk 
County, New York, and represented 3% of total per person clinical costs for each program. 
The share of total costs allocated to first surveillance colonoscopy, when performed, was 
small (less than 1%). The cost of office visits as a share of total per person clinical costs 
varied because of variations in the level of office visit use across sites.
DISCUSSION
The CRCSDP grantees contracted with a variety of providers to offer CRC screening using 
FOBT or colonoscopy. We found substantial variation by screening method and by program 
in the type and cost of clinical services provided and in service usage rates. Overall, we 
found that screening with FOBT was substantially less costly than screening by 
colonoscopy, both in terms of average cost per person and program-level costs. Costs also 
varied widely by site, however, in part because sites varied in their ability to negotiate 
prices, purchase in bulk, or limit reimbursement to certain aspects of screening. The 
percentage of program clients who had office visits and received follow-up services also 
varied by site. We identified the following 9 factors as possible contributors to these 
variations:
1. Local provider-reimbursement regulations: Hospital colonoscopy facilities used in 
the Baltimore City program were regulated by the Health Services Cost Review 
Commission (HSCRC); although Medicare pays the HSCRC rates, the regulated 
rates are higher than Medicare rates for nonregulated facilities.
2. Ability to negotiate special rates: Nebraska negotiated a flat fee for FOBT kits, 
purchased FOBT laboratory processing services in bulk, and set the maximum 
payment for colonoscopy at the Medicare rate. One hospital in Baltimore City 
negotiated a special rate that was below the HSCRC rate.
3. Patients’ contributions to the cost of clinical services: Some patients in Nebraska 
contributed copayments for clinical services they received.
4. Variations in providers’ policies regarding delivery of clinical services: For 
example, some providers required office visits before screening patients, whereas 
others did not. Providers in Suffolk County, New York served patients who were 
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referred by a PCP and, thus, required no office visit.14 In addition, some providers 
had follow-up visits with all patients screened, some with only some patients, and 
some with none of their patients.
5. Variations in the cost of living: We did not control for these variations, because we 
wanted to indicate the actual clinical costs at each site. Although variations in 
Medicare reimbursement rates (which are tied to local cost-of-living adjustments) 
contributed to the cost variations we observed, they did not account for all 
variation.
6. Variations in the percentage of patients advised to have follow-up tests who 
complied: Because our cost estimates reflect only those costs actually incurred, 
they are lower than what the total costs would have been if all patients had 
complied with follow-up recommendations.
7. Variations in the number of patients screened: Some programs (eg, the FOBT 
screening program in St. Louis) had very small patient populations for certain 
screening methods, which limited our ability to accurately capture rates and costs 
of follow-up or surveillance colonoscopies for these programs.
8. Variations in reimbursement policies: For example, the Nebraska program covered 
the laboratory costs for processing FOBTs, whereas the Greater Seattle program 
did not. In other programs, it was demonstrated that factors like these led to 
variation in colonoscopy costs in Maryland counties outside of Baltimore City 
(King M, Groves C, Dwyer DM; personal communication [Cost of Colonoscopy in 
Maryland Local Public Health Colorectal Cancer Screening Programs, Fiscal Year 
2009 Report, Cigarette Restitution Fund Program, Maryland Department of Health 
and Mental Hygiene, September 2010]).
9. Variations in procedures related to the colonoscopy (polypectomy, cautery, etc) not 
captured in these data: Costs for colonoscopy typically are based on the procedures 
performed during the colonoscopy. Although we observed differences in average 
costs across the categories of colonoscopies used here, these cost differences 
probably were driven by the different procedures performed during the 
colonoscopies.
The variations outlined above also affected the data collection process, which became much 
more complex than anticipated. Bulk payments for laboratory services for FOBT processing, 
for example, were not recorded with clinical billing data and, thus, had to be obtained from 
other accounting data. Similarly, partial payments recorded in billing data provided an 
incomplete picture of clinical costs and, thus, were excluded from the analysis, requiring 
additional effort to tease out which payments were complete. Future analysis of similar 
programs should account for variation in how cost data are reported.
In addition to the effects of the variations cited above, limitations to our study include the 
relatively small number of individuals who were screened. Finally, our ability to accurately 
estimate surveillance costs and to perform a comprehensive comparison of clinical costs 
between FOBT and colonoscopy screening programs was limited by the timeframe of the 
demonstration. The test intervals for FOBT and colonoscopy differ substantially, and 1 
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screening test occurs in a single step, whereas the other can be a 2-step process. Therefore, 
costs would need to be measured over a longer time horizon to make a programmatic cost 
comparison of clinical costs associated with FOBT and colonoscopy screening. This would 
allow for the ability to capture the costs associated with the annual or biannual FOBTs 
required for FOBT to be an effective screening test and to capture the costs associated with 
the diagnostic and then surveillance colonoscopies that would be generated with each 
additional year of annual or biannual FOBT.15 Similarly, because surveillance is ongoing, 
an accurate estimate of the clinical costs associated with surveillance would require a longer 
time horizon.
Despite these limitations, we were able to demonstrate that resource use and the cost of 
clinical services varied substantially among the 5 participants in the CRCSDP; that per unit 
procedure costs charged by some providers were different from local Medicare rates; and 
that, within the 4 years of this programmatic effort, clinical costs related to colonoscopy far 
exceeded those related to FOBT. These findings and our estimates of the clinical costs of 
specific CRC screening procedures and associated services can be used to guide 
administrators of established CRC screening programs as they evaluate their programs and 
look for ways to reduce costs and to guide health officials who plan to establish new, 
population-based CRC screening programs.
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